These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 30226476)

  • 41. Reversible cutaneous side effects of vismodegib treatment.
    Kwong B; Danial C; Liu A; Chun KA; Chang AL
    Cutis; 2017 Mar; 99(3):E19-E20. PubMed ID: 28398426
    [No Abstract]   [Full Text] [Related]  

  • 42. Histologic Findings of Tumor Lysis in Advanced Basal Cell Carcinoma Treated With Vismodegib.
    Powell EM; Stratton JS; Shendrik I; Blalock TW
    Dermatol Surg; 2016 Jul; 42(7):904-7. PubMed ID: 27191782
    [No Abstract]   [Full Text] [Related]  

  • 43. Vismodegib in advanced basal-cell carcinoma.
    Henkin RI
    N Engl J Med; 2012 Sep; 367(10):970; author reply 970-1. PubMed ID: 22931271
    [No Abstract]   [Full Text] [Related]  

  • 44. Vismodegib in basal cell carcinoma.
    Amaria RN; Bowles DW; Lewis KD; Jimeno A
    Drugs Today (Barc); 2012 Jul; 48(7):459-67. PubMed ID: 22844657
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Indications and limitations of vismodegib for basal cell carcinoma.
    Yin VT; Sniegowski M; Esmaeli B
    JAMA Ophthalmol; 2014 Jul; 132(7):905-6. PubMed ID: 25010179
    [No Abstract]   [Full Text] [Related]  

  • 46. Persistent alopecia induced by vismodegib.
    Alkeraye S; Maire C; Desmedt E; Templier C; Mortier L
    Br J Dermatol; 2015 Jun; 172(6):1671-1672. PubMed ID: 25546344
    [No Abstract]   [Full Text] [Related]  

  • 47. Indications and limitations of vismodegib for basal cell carcinoma--reply.
    Gill HS; Moscato EE; Silkiss RZ
    JAMA Ophthalmol; 2014 Jul; 132(7):906. PubMed ID: 25010181
    [No Abstract]   [Full Text] [Related]  

  • 48. Vismodegib, a hedgehog pathway inhibitor for adults with locally advanced or metastatic basal cell carcinoma.
    Wilkes GM
    Oncology (Williston Park); 2012 Aug; 26(8 Suppl Nurse Ed):31-3. PubMed ID: 25375009
    [No Abstract]   [Full Text] [Related]  

  • 49. Development of Basal Cell Carcinoma With Squamous Differentiation During Vismodegib Treatment.
    Feigenbaum L; Scott BL; Moye MS; Nijhawan RI
    Dermatol Surg; 2017 Jul; 43(7):989-991. PubMed ID: 28002101
    [No Abstract]   [Full Text] [Related]  

  • 50. Sonic Hedgehog Pathway Blockade After Surgical Debulk of Large Exophytic Basal Cell Carcinomas.
    Wirth PJ; Hobbs R; Billingsley E; Vidimos AT; Lam C
    Dermatol Surg; 2021 Aug; 47(8):1118-1119. PubMed ID: 34107497
    [No Abstract]   [Full Text] [Related]  

  • 51. Multiple highly and moderately differentiated squamous cell carcinomas of the skin during vismodegib treatment of inoperable basal cell carcinoma.
    Orouji A; Goerdt S; Utikal J; Leverkus M
    Br J Dermatol; 2014 Aug; 171(2):431-3. PubMed ID: 24446722
    [No Abstract]   [Full Text] [Related]  

  • 52. Vismodegib (ERIVEDGE°) In basal cell carcinoma: too many unknowns.
    Prescrire Int; 2015 Jan; 24(156):11-4. PubMed ID: 25729822
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vismodegib (Erivedge) for basal cell carcinoma.
    Med Lett Drugs Ther; 2012 Jul; 54(1394):53-4. PubMed ID: 22777303
    [No Abstract]   [Full Text] [Related]  

  • 54. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
    Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
    J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial.
    Basset-Séguin N; Hauschild A; Kunstfeld R; Grob J; Dréno B; Mortier L; Ascierto PA; Licitra L; Dutriaux C; Thomas L; Meyer N; Guillot B; Dummer R; Arenberger P; Fife K; Raimundo A; Dika E; Dimier N; Fittipaldo A; Xynos I; Hansson J
    Eur J Cancer; 2017 Nov; 86():334-348. PubMed ID: 29073584
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Vismodegib for basal cell carcinoma: targeted therapy in case of locally advanced or metastasised disease].
    Reinders MG; Terra JB; Reyners AK; Aarts MJ; de Haas ER; Mosterd K
    Ned Tijdschr Geneeskd; 2016; 160():D187. PubMed ID: 28000572
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mechanisms and efficacy of vismodegib in the treatment of basal cell carcinoma.
    Amin SH; Motamedi KK; Ochsner MC; Song TE; Hybarger CP
    Discov Med; 2013 Nov; 16(89):229-32. PubMed ID: 24229739
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A randomized phase II study evaluating vismodegib as neoadjuvant treatment of basal cell carcinoma preceding Mohs micrographic surgery: results and lessons learned.
    Soon SL; Ibrahim SF; Arron ST
    Br J Dermatol; 2019 Jul; 181(1):208-209. PubMed ID: 30628055
    [No Abstract]   [Full Text] [Related]  

  • 59. Multiple Lesions in Irradiated Skin.
    Wetzel M; Jung JY; Brown TS
    JAMA Oncol; 2019 May; 5(5):728-729. PubMed ID: 30653217
    [No Abstract]   [Full Text] [Related]  

  • 60. Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib.
    Bhutani T; Abrouk M; Sima CS; Sadetsky N; Hou J; Caro I; Chren MM; Arron ST
    J Am Acad Dermatol; 2017 Oct; 77(4):713-718. PubMed ID: 28780365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.